Results 11 to 20 of about 2,408 (165)
Вестник урологииIntroduction. Cytoreductive nephrectomy (CN) remains the standard of care in multimodal treatment for metastatic renal cell carcinoma (mRCC) with favorable prognosis.
D. V. Semyonov +3 more
doaj +2 more sources
Cytoreductive nephrectomy in the current treatment algorithm [PDF]
Therapeutic Advances in Medical Oncology, 2019 The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted ...
Teele Kuusk +4 more
doaj +6 more sources
Cytoreductive nephrectomy for metastatic renal cell carcinoma
Journal of the Scientific Society, 2013 Renal cell carcinoma is the most lethal urologic malignancy. Up to 30% of patients with kidney cancer have metastatic disease and 30% of those treated for local or locally advanced disease progress to metastases.
Rajendra B Nerli
doaj +3 more sources
Cytoreductive Nephrectomy: Still Necessary in 2021
European Urology Open Science, 2022 Arnaud Méjean, Axel Bex
doaj +3 more sources
Cytoreductive Nephrectomy in 2021: Obsolete but Necessary
European Urology Open Science, 2022 Umberto Capitanio +3 more
doaj +3 more sources
New Paradigms for Cytoreductive Nephrectomy. [PDF]
Cancers (Basel), 2022 The role of CN in the treatment of metastatic renal cell carcinoma (mRCC) has been studied over the course of the past few decades. With the advent of immuno-oncologic (IO) agents, there has been a paradigm shift in the treatment of RCC. Within this new era of cancer care, the role of CN is unclear. There are several studies currently underway that aim
Lichtbroun BJ +4 more
europepmc +3 more sources
Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future? [PDF]
BJU IntObjective To investigate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) treated with immune‐checkpoint inhibitors (ICIs). Methods A narrative review was carried out using PubMed and searching for English articles published from January 2015 to May 2025.
Flammia RS +8 more
europepmc +2 more sources
A rapid progression of new metastatic lesion after cytoreductive nephrectomy: A case report
Urology Case Reports, 2021 A 55-years-old man presented with the chief complaint of right flank mass and hematuria. CT scan revealed clinical T4 RCC. Cytoreductive nephrectomy (CN) was performed with histopathology result of Papillary renal cell carcinoma.
Steven Steven, Ferry Safriadi
doaj +1 more source
Frontiers in Oncology, 2021 BackgroundIt is highly contested whether cytoreductive nephrectomy for treating advanced renal cell carcinoma (RCC) with sarcomatoid features (sRCC) benefits overall survival. Patients with sRCC are known to have a poor prognosis, and these tumors have a
Jacob J. Adashek +9 more
doaj +1 more source
Case Reports in Oncology, 2023 The role of cytoreductive nephrectomy has become unclear since the introduction of immunotherapy which is now the backbone of the treatment for metastatic renal cell carcinoma. Different combinations are used based on the prognosis.
Amir F. Beirat +3 more
doaj +1 more source